Abstract: The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.

Abstract: The present invention relates to the enhancement of the efficacy of anticancer agents by a composition comprising an aqueous phase, an oil phase, EPA and DHA for use in the treatment of solid tumors, wherein EPA and DHA are present in an amount of at least 65% based on the total weight of the oil phase wherein the composition comprises EPA and DHA in a weight ratio between 1:2 and 1:4, or wherein the composition comprises EPA and DHA in a weight ratio between 6:1 and 4:1 and wherein the treatment comprises administering the composition and administering at least one anticancer agent.

Abstract: The present invention relates to the treatment of liver diseases. In particular, it relates to a composition for use in treating and/or preventing a liver disease in a subject, wherein said composition comprises eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the ratio of EPA to DHA is at least 2:1.

Abstract: The present disclosure relates to L-glutamine for use in preserving, improving or restoring kidney function or for decelerating and/or attenuating a decline in kidney function.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.

Abstract: The invention provides an additive for binding the residual moisture in the residue salt of a salt heap to reduce the heap water content, wherein the additive has hydraulically and/or pozzolanically setting properties.

Abstract: The invention provides an additive for binding the residual moisture in the residue salt of a salt heap to reduce the heap water content, wherein the additive has hydraulically and/or pozzolanically setting properties.

Abstract: The invention relates to a mixture to be applied onto a dump of residue salt as an infiltration-inhibiting layer for reducing the occurrence of pile water caused by precipitation, wherein the mixture comprises residue salt and a mineral additive which is poorly soluble to insoluble and has hydraulically and/or pozzolanically setting properties.

Abstract: The invention relates to a base seal of a dump, in particular a residual salt dump, said seal comprising two layers disposed on top of one another. The upper layer has a mixture of gravel, sand and bentonite or powered clay with a permeability coefficient of k?10?9 m/s and the lower layer has a mixture of sand and bentonite or powered clay with a permeability coefficient of k?5*10?10 m/s.

Abstract: A hand-held computer for the display and processing of medical data having a portable housing (2), a processor with both a working memory and a hard disk memory, a touch screen connected to the processor (3), a rechargeable battery, and corresponding I/O interfaces (10-17). The processor is programmed with a medical image processing and diagnosis software for receiving medical image data in the DICOM standard, wherein the maximum displayable number of differentiated individual image displays is limited in number, corresponding to the size of the touch screen (3). A passive pen (4) is provided to operate the touch screen (3) as an additional input device. An infrared interface is provided for feeding in medical data from a mainframe computer and/or a computer network. The processor also has a data connection with a radio reception and transmission device for wireless data exchange via a mobile radio network, and includes a modem, integrated in the processor.